Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model Jiang Liu, MD, Penny C.

Slides:

Advertisements

Similar presentations

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

Advertisements

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model Jiang Liu, MD, Penny C.

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model Licun Wu, MD, Zhihong.

Saikosaponin-D Enhances Radiosensitivity of Hepatoma Cells under Hypoxic Conditions by Inhibiting Hypoxia-Inducible Factor-1α Cell Physiol Biochem 2014;33:37-51.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy Mir Alireza Hoda, MD, Amir Mohamed, BSc,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer Lanxi Song, MS, Matthew A. Smith, PhD,

Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma Jia Wang, Tong Yang, Gaofeng Xu, Hao Liu, Chunying.

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer Vinita Singh-Gupta, PhD, Michael.

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis Ruo-Chia Tseng, PhD, Jia-Ming Chang,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression.

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

RET Mutation and Expression in Small-Cell Lung Cancer

The impact of the IGF-1 system of cancer cells on radiation response – An in vitro study Senthiladipan Venkatachalam, Esther Mettler, Christian Fottner,

RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases Robert E. Miller,

Chandra M.V. Goparaju, PhD Journal of Thoracic Oncology

Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human.

Functional Investigation of Fas Ligand Expressions in Human Non-Small Cell Lung Cancer Cells and Its Clinical Implications Yidan Lin, MD, PhD, Lunxu.

P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue Marco Lo Iacono, PhD, Valentina Monica,

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death Kwang Woon Kim, PhD, Christina K. Speirs,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL James.

Regulation of tumor angiogenesis by integrin-linked kinase (ILK)

Pulmonary Fibroblasts Induce Epithelial Mesenchymal Transition and Some Characteristics of Stem Cells in Non-Small Cell Lung Cancer Yasushi Shintani,

Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival Zarah Glad.

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer Silvan Becker, MD, Boyka Markova, PhD, Rainer.

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Takeshi Isobe, MD, PhD, Amir Onn, MD, Daniel Morgensztern, MD, Jörg J

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Joshua S. McLane, Lee A. Ligon Biophysical Journal

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Prognostic Impact of Fibroblast Growth Factor 2 in Non-small Cell Lung Cancer: Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival Tom Donnem,

Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice Jörg.

Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression Toran Sanli,

Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small.

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

BV6, an IAP Antagonist, Activates Apoptosis and Enhances Radiosensitization of Non- small Cell Lung Carcinoma In Vitro Wenyan Li, MD, PhD, Bo Li, MD,

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Angiogenic Markers Show High Prognostic Impact on Survival in Marginally Operable Non-small Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy

Volume 19, Issue 1, Pages (April 2017)

Ly6/uPAR-Related Protein C4

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non- small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan.

Volume 19, Issue 1, Pages (April 2017)

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance Xin Dong, MD, Dong Lin,

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Integrin-Linked Kinase Inhibitor KP-392 Demonstrates Clinical Benefitsin an Orthotopic Human Non-small Cell Lung Cancer Model Jiang Liu, MD, Penny C. Costello, PhD, Nhu-An Pham, MSc, Melania Pintillie, MSc, Mogjan Jabali, PhD, Jasbinder Sanghera, PhD, Ming-Sound Tsao, MD, Michael R. Johnston, MD Journal of Thoracic Oncology Volume 1, Issue 8, Pages 771-779 (October 2006) DOI: 10.1016/S1556-0864(15)30405-6 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 (A) ILK activity was measured in H460 cells after 3-hour incubation with KP-392 or solvent (control). Background levels included reagents without cells. All treatments were performed in triplicate; error bars represent ±SD of each sample group. KP-392 significantly inhibited the ILK activity derived from the H460 cells in this biochemical assay. (B) Detection of decreasing amounts of phospho-PKB/AKT by Western analysis resulted from a dose-dependent effect of KP-392 inhibition on ILK. Cell lysates were harvested after 3 hours of drug incubation. There was a significant decrease in phospho-PKB/AKT (SER473) at 100 μM drug. (C, D) Immunocytochemical analysis of DMSO control (C) and KP-392–treated (D) H460 cells. Phospho-PKB (Ser-473) level was significantly reduced following 3 hours of treatment with KP-392. Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan–Meier survival curves of vehicle-treated control animals and three treatment arms, including cisplatin alone, KP-392 alone, and cisplatin + KP-392. Both KP-392 alone and cisplatin + KP-392 significantly prolonged survival compared with vehicle controls (p = 0.0418 and p < 0.0001, respectively). The combined cisplatin + KP-392 regimen showed better survival than cisplatin treatment alone (p < 0.0006). Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Image analysis was performed on H & E stained whole-tumor sections for the quantification of percent area of necrosis. Whiskers plot the minimum and maximum value, and a box plots the first quantile, median, and third quantile. The median for KP-392–treated animals is higher than vehicle-treated controls but not significant (p = 0.11). Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 A representative ILK-labeled tissue array image (A), captured using a Sprint Scan 35 Plus (Polaroid, Waltham, MA), shows groups of six cores per tumor specimen. An image of a typical core from an array stained with ILK shows moderate to intense expression in tumor and stromal cells (B), 20× objective lens. Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 An IHC score was applied to evaluate phospho–protein kinase B (Ser473) and phospho– extracellular signal-regulated kinase (Thr202/Thr204) in tissue arrays (A). A box plots the first quantile, median, and third quantile, and whiskers plot the minimum and maximum value. The median value of nuclear phospho–protein kinase B staining in KP-392–treated animals is significantly less than control, p < 0.01. Representative images from the control tissue array (B and C) specimens showing intense and weak phospho–protein kinase B stain, respectively (40× objective lens, ScanScope CS, Aperio Technologies, Vista, CA). Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Physical health of animals evaluated by skin coat condition, respiratory movement, and mobility at day 30 following tumor implantation. They were scored as 0 (normal), 1 (mild condition), 2 (moderate condition), 3 (severe condition), or 4 (critical condition). No animal reached condition 4 in accordance with the humane end point established by animal care regulations. The data are presented as mean ± SD. (A) Percentage of animals reaching grade 3 for skin coat condition. (B) Percentage of animals reaching grade 3 for respiratory distress. (C) Percentage of animals reaching grade 3 for mobility/activity. Journal of Thoracic Oncology 2006 1, 771-779DOI: (10.1016/S1556-0864(15)30405-6) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions